Concepedia

Author

Janusz Milanowski

Medical University of LublinORCID

Also Known As

Anna Lowczak, G Cholewa, J Milanowski, J. Milanowski, JANUSZ MILANOWSKI, Janusz Milanowski, Janusz Milanowski, Karina Jahnz—Rö, Katarzyna Szmygin-Milanowska, Milanowski Janusz

365

Publications

4.7K

Citations

32

H-Index

107

Concepts

All Affiliations

Medical University of LublinInstytut Medycyny Wsi im. Witolda ChodźkiPoznan University of Medical SciencesThe Maria Sklodowska-Curie National Research Institute of OncologyPostgraduate School of Molecular Medicine
JM

About

Janusz Milanowski is an author at Medical University of Lublin specializing in medicine, pathology, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

39

1.5K

2

Allergy

12

14

364

3

Public Health

8

8

406

4

Health Sciences

3

3

134

5

Engineering

1

1

22

Janusz Milanowski

×

89

Publications

2.9K

Citations

29

H-Index

YearCitations

Phenotypes of organ involvement in sarcoidosis

Jonas C. Schupp, Sandra Freitag‐Wolf, Elena Bargagli,

European Respiratory Journal

2018

237

ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia

David C. Currow, Jennifer S. Temel, Amy P. Abernethy,

Annals of Oncology

2017

172

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

Enriqueta Felip, Andrea Ardizzoni, Tudor–Eliade Ciuleanu,

European Journal of Cancer

2020

155

Twelve-Month Safety and Efficacy of Inhaled Fluticasone Propionate in Children Aged 1 to 3 Years With Recurrent Wheezing

Hans Bisgaard, David B. Allen, Janusz Milanowski,

PEDIATRICS

2004

152

Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report

Tomasz Powrózek, Paweł Krawczyk, Tomasz Kucharczyk,

Medical Oncology

2014

104

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau,

The Lancet Oncology

2023

90

Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients

Tomasz Powrózek, Paweł Krawczyk, Marcin Nicoś,

Clinical & Translational Oncology

2015

67

Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers

Tomasz Powrózek, Paweł Krawczyk, Dariusz M. Kowalski,

Translational research

2015

67

Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO)

Johan Vansteenkiste, Fabrice Barlési, Cornelius F. Waller,

Annals of Oncology

2015

67

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

Giorgio V. Scagliotti, Igor Bondarenko, Fiona Blackhall,

Annals of Oncology

2014

64

Page 1